GARS1 and Charcot-Marie-Tooth disease type 2D: Given that 1) mutant GlyRS competes with VEGF-A for Nrp1 binding10, 2) GlyRS is secreted7, 10, 25 and found circulating in serum of humans and mice25, and 3) vascular impairment can contribute to neurodegeneration26, we decided to assess the effect of mutant GlyRS on the vascular system of the GarsC201R/+ murine model of CMT2D.